In a preclinical study, the antibody-drug conjugate indatuximab ravtansine (BT062) showed complete remission, i.e., >95% reduction of median tumor volume in relation to controls, in triple-negative breast cancer xenografts with strong expression of CD138 in IHC [24]. Here, SDC1 is linked to neoplasm.